Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors
- 163 Downloads
Introduction: Lenalidomide is an immunomodulatory derivative of thalidomide with significantly greater in vitro activity and a different toxicity profile. In preclinical trials it has shown synergy with chemotherapy.
Patients and methods: Primary objective of this study was to determine the maximum tolerated doses of docetaxel and carboplatin when combined with oral lenalidomide in a standard phase I study design. Between September 2004 and May 2005, 14 patients with pathologically proven solid tumors, ≤2 prior chemotherapy regimens, performance status ECOG 0/1, and adequate organ function were enrolled. Dose limiting toxicities (DLT) were defined as ≥ grade 3 non-hematological, or grade 4 hematological toxicity. No growth factors were used during cycle 1.
Results: Three of four patients treated at dose level 1, docetaxel 60 mg/m2 and carboplatin AUC 6 on Day 1, and lenalidomide 10 mg orally daily on Days 1–14 of a 21 day cycle experienced DLT (grade 3 electrolyte changes in two patients, and grade 4 neutropenia in one patient). Ten patients were treated at dose level −1, docetaxel 60 mg/m2 and carboplatin AUC 6 on Day 1, and lenalidomide 5 mg orally daily on Days 1–14 of a 21 day cycle with one DLT (Grade 4 neutropenia). There were no treatment-related deaths or irreversible toxicities. Of the 14 response-evaluable patients, five achieved a partial response (5 out of 9 patients with non-small cell lung cancer.
Conclusions: Docetaxel 60 mg/m2 and carboplatin AUC 6 on Day 1, with lenalidomide 5 mg orally daily on Days 1–14 days of a 21 day cycle is the maximum tolerated dose without the use of prophylactic growth factors. This combination is active and further evaluation in a phase II trial is warranted.
KeywordsLenalidomide Revlimid Phase I study Solid tumor Docetaxel Carboplatin
- 18.Sandler Aea (2005) Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. In: ASCO annual meeting; 2005.Google Scholar
- 20.Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216PubMedCrossRefGoogle Scholar
- 21.Belani CPHY, Ramnathan R et al (1997) Docetaxel and carboplatin: A phase ! and pharmacokinetic trial for advanced non-hematological malignancies. In: ASCOGoogle Scholar
- 22.Giannakakis TKS, Theodoropoulos E, Kouroussis C, Michailakis E, Papadouris S, Tsitoura M, Kalbakis K, Souglakos J, Agelaki S, Vardakis N, Georgoulias V (2002) A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer. Anticancer Res 22(6B):3743–3748PubMedGoogle Scholar
- 24.Hussein MA MAK, Brand C, Pearce GL, Reed J, Bruening K, Sartori P, Srkalovic G, Olesnyckyj M, Knight R, Balinski K, Zeldis J (2003) Doxil (D), Vincristine (V), reduced frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a phase I/II trial in advanced relapsed/refractory multiple myeloma (Rmm) patients. Session type: Oral session. Blood 63a–64a:abstract 208Google Scholar
- 25.Marsh L, Khan M, Needle M, Amato R (2006) Phase II study of lenalidomide in pts with metastatic renal cell cancer. Abstract 4533. In: ASCOGoogle Scholar
- 26.Choueiri T, Dreicer R, Rini B, Elson P, Garcia J, Mekhail T, Bukowski R (2006) Phase II study of lenalidomide in pts with metastatic renal cell carcinoma. Abstract 4539. In: ASCOGoogle Scholar
- 27.Papdopoulos K, Mendelson D, Preston G, Lopez A, Ricart A, Schwartz G, Needle M, Gordon M (2005) A phase I study of lenalidomide and weekly docetaxel in patients with advanced solid tumors. In: AACR-NCI-EORTC international conference on molecular targets and cancer therapeuticsGoogle Scholar